| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABBVIE INC | 11,029,800 | 695,649,000 | 28.12% | ||
| 2 | PROTHENA CORP PLC | 10,301,751 | 617,384,000 | 24.96% | ||
| 3 | REYNOLDS AMERICAN INC | 7,608,324 | 358,732,000 | 14.50% | ||
| 4 | ALKERMES PLC SHS | 7,549,033 | 355,031,000 | 14.35% | ||
| 5 | Theravance Biopharma Inc | 9,407,137 | 340,915,000 | 13.78% | ||
| 6 | BIOGEN INC | 170,430 | 53,350,000 | 2.16% | ||
| 7 | GILEAD SCIENCES INC | 486,800 | 38,516,000 | 1.56% | ||
| 8 | NORTHWEST BIOTHERAPEUTICS INC | 25,915,937 | 14,062,000 | 0.57% |
Portfolio data is normalized using SEC Form 13F filings, including the Restatement filing (0001213900-17-005686, filed 2017.05.22).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
